Vaxcyte, Inc. (PCVX) FY2025 10-K Annual Report
Vaxcyte, Inc. (PCVX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vaxcyte, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of proprietary pneumococcal conjugate vaccines
- • New manufacturing agreement with Lonza Ltd effective January 2026 for development and commercial supply of vaccine components
- • Strategic move to secure long-term manufacturing capacity with fees in mid- to high-eight-figures Swiss Francs annually through 2038 plus renewals
- • License received from Lonza: perpetual, irrevocable, royalty-free rights to use Lonza’s intellectual property related to product and manufacturing process
- • Contract includes termination rights with termination fees in low-eight-figures Swiss Francs, ensuring operational flexibility and risk mitigation
Management Discussion & Analysis
- • No revenue generated in FY 2026 as Vaxcyte is clinical-stage; net losses $766.6M in 2025 vs $463.9M in 2024 vs $402.3M in 2023
- • Operating losses increased due to advancing clinical trials and manufacturing scale-up; cash, equivalents, investments $2.44B as of Dec 31, 2025
- • Best performing pipeline: VAX-31 Phase 3 adult PCV program initiated with ~3,560 adults dosed; FDA breakthrough therapy designation expanded to pneumonia prevention
- • Capital raise: February 2026 public offering gross proceeds $632.5M from 12.65M shares at $50 each
- • Forward outlook: Phase 3 data awaited late 2026 (adult) and first half 2027 (infant); planning BLA submission post Phase 3; risks include development timelines and regulatory approvals
Risk Factors
- • Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm
- • SVP IT with 30+ years experience leads cybersecurity risk management and incident response
- • Cybersecurity incident escalation to President and CFO, with audit committee oversight and quarterly reporting
Vaxcyte, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$767M
▼ -65.2% YoY
ROE
-28.5%
▼ -1451bp YoY
Total Assets
$3.0B
▼ -14.5% YoY
EPS (Diluted)
$-5.63
▼ -48.2% YoY
Operating Cash Flow
-$656M
▼ -44.8% YoY
Source: XBRL data from Vaxcyte, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vaxcyte, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.